Benchling provides an R&D Cloud software platform that powers the biotechnology industry. Led by CEO Sajith Wickramasekara, the company says more than 200,000 scientists at over 600 companies and 7,000 research institutions globally use its platform. Since its Series E in April the company has introduced new capabilities, including support for Early Development and RNA therapeutics. Benchling recently hired Salesforce executive Lindsey Irvine as chief marketing officer. The company will use the funding to continue investing in product development and global expansion, with particular emphasis on its EMEA presence. In its first year in EMEA Benchling reached over 90 European customers, including Cutiss AG, Sanofi, Selexis SA and Syngenta, and grew its European team to more than 60 people. Benchling offers a life sciences R&D cloud platform used to design DNA, collaborate on experiments, automate data capture, manage research workflows and organize complex experimental datasets. Since launching in 2012, more than 300,000 scientists and 1,000 R&D organizations have adopted the platform. Customers include Gilead Sciences, Sanofi, Regeneron, Corteva Agrisciences and Sana Biotechnology. The company says it doubled its annual recurring revenue for the fourth year in a row while adding more than 150 customers across industries. Benchling has opened an EMEA headquarters in Zurich and plans to invest in product development and global expansion to support enterprise customers and biotech hubs. Benchling provides a unified R&D cloud platform powering the life science industry, with products including Notebook, Molecular Biology, Registry, Inventory, Request & Workflow Management, and Insights. The platform centralizes complex experimental datasets and optimizes R&D processes for multinational pharmaceutical corporations, emerging biotechnology companies, and research institutions. Since launching in 2012, more than 230,000 scientists and over 1,000 R&D organizations have adopted Benchling. Led by founder and CEO Saji Wickramasekara, the company intends to use new capital to build advanced product capabilities, expand its international presence, and drive broader adoption across leading R&D organizations. Benchling closed a $50M Series D to support these initiatives. Benchling is a cloud-based life sciences R&D platform that enables scientists to design DNA, collaborate on experiments, manage research workflows and make critical R&D decisions. Its solution features Notebook, Molecular Biology, Registry, Inventory, and Request & Workflow Management tools. The platform is used by over 170,000 scientists globally across multinational pharmaceutical corporations, emerging biotechnology companies, and major research institutions. Customers include academic labs at Harvard, MIT, Stanford, and Berkeley, as well as Zoetis, Beam Therapeutics, Zymergen and Regeneron Pharmaceuticals. Led by CEO Sajith Wickramasekara, the company will use the Series C funds to grow globally, extend its product lead and expand commercial relationships. Benchling is based in San Francisco, CA. Benchling offers a unified, cloud-based R&D informatics platform purpose-built for biologics, with applications including Lab Notebook, Molecular Biology, Bioregistration, Sample Tracking, and Request & Workflow Management. The platform is used by more than 100,000 scientists across enterprise and academic labs and has been adopted by customers such as Regeneron, Incyte, Editas Medicine, Agenus, Zymergen, and Obsidian Therapeutics. Since its last funding round in 2016, Benchling reports its ARR has grown 500% and its customer base has tripled year-over-year; customers report up to a 4x increase in productivity and up to a 67% reduction in emails. Benchling says it accelerates collaboration and knowledge retention for R&D teams, addressing reliance on paper notebooks and legacy systems. With the new funding, the company plans to accelerate product development, continue hiring (recent additions include Kaiser Mulla-Feroze as CMO and Sam Partovi for sales), and expand its enterprise and research-lab customer base. The company highlights use at major research institutions such as Harvard, MIT, UC Berkeley, and Stanford.

Total raised

$412M

Funding rounds

8

Latest round

Series F

Latest activity

Nov 2021